Crossmark Global Holdings Inc. Purchases Shares of 16,117 Calliditas Therapeutics AB (publ) (NASDAQ:CALT)

Crossmark Global Holdings Inc. acquired a new position in Calliditas Therapeutics AB (publ) (NASDAQ:CALT) in the 3rd quarter, HoldingsChannel.com reports. The institutional investor acquired 16,117 shares of the company’s stock, valued at approximately $655,000.

Calliditas Therapeutics AB (publ) Price Performance

Shares of Calliditas Therapeutics AB (publ) stock opened at $40.00 on Friday. The stock’s 50-day moving average is $40.00 and its 200 day moving average is $37.02. Calliditas Therapeutics AB has a one year low of $15.25 and a one year high of $43.00. The firm has a market cap of $1.19 billion, a price-to-earnings ratio of -21.62 and a beta of 1.77. The company has a debt-to-equity ratio of 9.44, a current ratio of 2.69 and a quick ratio of 2.59.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.09. The firm had revenue of $52.36 million for the quarter, compared to analysts’ expectations of $42.89 million. Calliditas Therapeutics AB (publ) had a negative return on equity of 212.04% and a negative net margin of 30.18%. During the same period in the prior year, the business earned ($0.33) EPS. Equities research analysts anticipate that Calliditas Therapeutics AB will post -0.99 EPS for the current year.

About Calliditas Therapeutics AB (publ)

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia.